Abstract
Saccharomyces cerevisiae is a common colonizer of the human gastrointestinal system as a benign organism. Enteral supplementation of this yeast as a probiotic product is effective in the treatment of antibiotic associated diarrhae. In rare occasions it can cause invasive infections. We present two fungemia cases in an intensive care unit following probiotic treatment containing S. boulardii. We are warning the safety of probiotic treatment in critically ill patients.
Keywords:
Fungemia; Intensive care unit; Probiotic; Saccharomyces cerevisiae (boulardii).
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Adult
-
Aged, 80 and over
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects
-
Antifungal Agents / therapeutic use
-
Critical Illness
-
Diarrhea / microbiology
-
Diarrhea / therapy
-
Enteral Nutrition
-
Fatal Outcome
-
Female
-
Fungemia / drug therapy
-
Fungemia / etiology*
-
Fungemia / microbiology*
-
Humans
-
Intensive Care Units*
-
Male
-
Probiotics / administration & dosage
-
Probiotics / adverse effects*
-
Saccharomyces cerevisiae / drug effects
-
Saccharomyces cerevisiae / genetics
-
Saccharomyces cerevisiae / isolation & purification*
-
Shock, Septic / etiology
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Antifungal Agents